Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.73USD
17 Aug 2017
Change (% chg)

$0.09 (+1.36%)
Prev Close
$6.64
Open
$6.62
Day's High
$6.73
Day's Low
$6.27
Volume
6,669
Avg. Vol
7,911
52-wk High
$7.32
52-wk Low
$4.43

CPIX.OQ

Chart for CPIX.OQ

About

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcyste... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $105.39
Shares Outstanding(Mil.): 15.90
Dividend: --
Yield (%): --

Financials

  CPIX.OQ Industry Sector
P/E (TTM): -- 31.64 32.84
EPS (TTM): -0.44 -- --
ROI: -9.27 15.30 14.86
ROE: -10.03 16.32 16.11

BRIEF-Cumberland Pharmaceuticals Q2 adjusted loss per share $0.05

* Cumberland Pharmaceutical reports double digit revenue growth for the fourth consecutive quarter

Aug 08 2017

BRIEF-Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support

* Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support

Jul 31 2017

BRIEF-Stonepine Capital Management reports 6.8 percent passive stake in Cumberland Pharmaceuticals

* Stonepine Capital Management Llc reports 6.8 percent passive stake in Cumberland Pharmaceuticals Inc as of May 9 - SEC filing Source text for Eikon: (http://bit.ly/2qA4bqN) Further company coverage:

May 19 2017

BRIEF-Cumberland Pharmaceuticals reports q1 adjusted EPS $0.02

* Cumberland pharmaceuticals reports revenue growth of 25% in first quarter 2017

May 15 2017

BRIEF-Cumberland Pharmaceuticals entered into a co-promotion partnership with Poly Pharmaceuticals for Kristalose within U.S.

* Cumberland Pharmaceuticals Inc - Entered into a co-promotion partnership with Poly Pharmaceuticals Inc for Kristalose within United States

Apr 26 2017

BRIEF-Cumberland Pharmaceuticals says caldolor demonstrates significant post surgical pain reduction and decrease in opioid use

* Cumberland Pharmaceuticals Inc says Caldolor demonstrates significant post surgical pain reduction and decrease in opioid use Source text for Eikon: Further company coverage:

Mar 27 2017

Earnings vs. Estimates